Recombinant PCSK9 (Lodelcizumab Biosimilar) antibody
Research Grade
Reactivity: Human
ELISA
Host: Mammalian Cells
Monoclonal
unconjugated
Recombinant Antibody
-
- Target
- PCSK9 (Lodelcizumab Biosimilar)
- Antibody Type
- Recombinant Antibody
- Reactivity
- Human
- Host
-
Mammalian Cells
- Expression System
- Mammalian cells
- Clonality
- Monoclonal
- Application
- ELISA
- Purpose
- Lodelcizumab Biosimilar - Anti-PCSK9 mAb
- Characteristics
- Antibody Type: IgG1-kappa
- Purification
- Recombinant antibody expressed in mammalien cells and purified.
- Grade
- Research Grade
- Isotype
- IgG1 kappa
-
- Restrictions
- For Research Use only
-
- Buffer
- PBS pH 7.5
- Storage
- -80 °C
- Storage Comment
- store at -80°C
-
- Target
- PCSK9 (Lodelcizumab Biosimilar)
- Target Type
- Biosimilar
- Background
-
LGT209,NVP-LGT209
Ligelizumab (QGE031) is a humanized monoclonal antibody (mAb) designed for the treatment of severe asthma and chronic spontaneous urticaria. - CAS-No
- 1355338-54-3
-
You are here:
